Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct;24(10):1066-1074.
doi: 10.1111/hiv.13501. Epub 2023 May 25.

Impact of weight gain with dolutegravir on antiretroviral adherence and viral suppression in four African countries

Matthew L Romo  1   2 , Allahna L Esber  1   2 , John Owuoth  3   4 , Jonah Maswai  1   5 , Valentine Sing'oei  3   4 , Michael Iroezindu  1   6 , Emmanuel Bahemana  1   7 , Hannah Kibuuka  8 , J Sean Cavanaugh  1 , Neha Shah  1 , Julie A Ake  1 , Trevor A Crowell  1   2 ; AFRICOS Study Group
Affiliations

Impact of weight gain with dolutegravir on antiretroviral adherence and viral suppression in four African countries

Matthew L Romo et al. HIV Med. 2023 Oct.

Abstract

Objective: We hypothesized that total body weight (TBW) gain after switching antiretroviral therapy (ART) regimen to tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD) may negatively impact ART adherence and viral load (VL) and therefore sought to examine these associations.

Methods: The ongoing African Cohort Study (AFRICOS) enrols people with HIV at 12 facilities in Kenya, Nigeria, Tanzania and Uganda supported by The US President's Emergency Plan for AIDS Relief. Among ART-experienced participants who switched to TLD, we used multivariable multinomial logistic regression to examine associations between pre-/post-TLD changes in percentage TBW (≥5% gain, <5% change, ≥5% loss) and changes in self-reported ART adherence (0, 1-2, ≥3 days missed doses in past 30 days) and VL [(<50 copies/mL (undetectable), 50-999 copies/mL (detectable, but suppressed), ≥1000 copies/mL (unsuppressed)].

Results: Among 1508 participants, median time from starting TLD to follow-up was 9 months (interquartile range: 7-11). Overall, 438 (29.1%) participants experienced a TBW gain ≥5%, which was more common among females than among males (32.2% vs 25.2%, p = 0.005) and participants switching from efavirenz [32.0% vs nevirapine (19.9%) and boosted protease inhibitor (20.0%); p < 0.001]. Compared with a TBW change <5% [950 (63.0%) participants], TBW gain ≥5% was not significantly associated with more days with missed ART doses [adjusted odds ratio (aOR) = 0.77, 95% confidence interval (CI): 0.48-1.23] or VL becoming detectable and/or unsuppressed (aOR = 0.69, 95% CI: 0.41-1.16).

Conclusions: Although a substantial proportion of participants experienced weight gain after switching to TLD, we did not identify a significant impact on adherence or virological outcomes.

Keywords: HIV integrase inhibitors; antiretroviral agents; drug-related side effects and adverse reactions; medication adherence; weight gain.

PubMed Disclaimer

References

REFERENCES

    1. Clinton Health Access Initiative. HIV market report: the state of the HIV market in low- and middle-income countries. Available from: https://www.clintonhealthaccess.org/report/2022-hiv-market-report-the-st.... Accessed 31 March 2023
    1. Kanters S, Vitoria M, Zoratti M, et al. Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: a systematic literature review and network meta-analysis. EClinicalMedicine. 2020;28:100573.
    1. Dorward J, Sookrajh Y, Khubone T, et al. Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study. Lancet HIV. 2023;10:e284-e294. doi:10.1016/S2352-3018(23)00047-4
    1. Calmy A, Tovar Sanchez T, Kouanfack C, et al. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon. Lancet HIV. 2020;7:e677-e687.
    1. Venter WDF, Sokhela S, Simmons B, et al. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV. 2020;7:e666-e676.

Publication types

LinkOut - more resources